Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis has reported that the FDA has approved Diovan, an angiotensin receptor blocker, for the treatment of high blood pressure in children and adolescents aged between six and 16.
Subscribe to our email newsletter
Experts suggest that the increase in incidence of high blood pressure among children and adolescents is linked to the growing pediatric obesity epidemic.
John Orloff, senior vice president, medical and drug regulatory affairs, Novartis Pharmaceuticals, said: “Novartis believes it is important to provide physicians with treatment options such as Diovan which are effective in treating high blood pressure in this vulnerable population of children and adolescents.”